66104-23-2
Product Name:
Pergolide mesylate salt
Formula:
C20H30N2O3S2
Synonyms:
8β-[(Methylthio)methyl]-6-propylergoline methanesulfonate salt;Pergolide mesylate salt;Pergolide methanesulfonate salt
Inquiry
CHEMICAL AND PHYSICAL PROPERTIES
| Solubility | 2.3 [ug/mL] (The mean of the results at pH 7.4) |
|---|---|
| Collision Cross Section | 177.4 Ų [M+H]+ [CCS Type: TW, Method: calibrated with polyalanine and drug standards] |
SAFETY INFORMATION
| Signal word | Danger |
|---|---|
| Pictogram(s) |
 Skull and Crossbones Acute Toxicity GHS06 |
| GHS Hazard Statements |
H300:Acute toxicity,oral |
COMPUTED DESCRIPTORS
| Molecular Weight | 410.6 g/mol |
|---|---|
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 5 |
| Rotatable Bond Count | 4 |
| Exact Mass | 410.16978517 g/mol |
| Monoisotopic Mass | 410.16978517 g/mol |
| Topological Polar Surface Area | 107 Ų |
| Heavy Atom Count | 27 |
| Formal Charge | 0 |
| Complexity | 480 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 3 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently-Bonded Unit Count | 2 |
| Compound Is Canonicalized | Yes |
PRODUCT INTRODUCTION
description
Pergolide mesylate is a methanesulfonate salt obtained from pergolide by mixing eqimolar amount of pergolide and methanesulfonic acid. A dopamine D2 receptor agonist which also has D1 and D2 agonist properties, it is used in the management of Parkinson's disease, although it was withdrawn from the U.S. and Canadian markets in 2007 due to an increased risk of cardiac valve dysfunction. It has a role as an antiparkinson drug, a dopamine agonist and a geroprotector. It contains a pergolide(1+).